Advancements in Antiviral Treatment by Bioxytran
ProLectin-M is currently being developed under an active Investigational New Drug (IND) application with the FDA.
Bioxytran, Inc. (OTCQB: BIXT), a pioneering clinical-stage biotechnology company, is making strides toward improving treatments for viral infections. With its innovative approach, Bioxytran is thrilled to announce advancements in the development of its broad-spectrum antiviral drug known as ProLectin-M. Recent successful dosing in a clinical trial marks a substantial step forward toward potentially transforming the treatment methodologies for respiratory infections.
ProLectin-M represents Bioxytran's primary focus in drug development. It effectively targets galectin folds within the spike proteins of various viruses, including SARS-CoV-2 and influenza. Studies already published in reputable journals highlight ProLectin-M's high neutralization ability, achieving notable results in clinical trials. By the seventh day of treatment, trial subjects exhibited negative PCR tests, and by the third day, 88% showed a significant response, showcasing the drug's effectiveness without viral rebounds during the two-week observation.
Collaboration and Vision for Future Treatments
Dr. David Platt, CEO of Bioxytran, has expressed the importance of this moment for the company and the broader field of virology. He emphasizes how ProLectin-M's design, crafted with advanced techniques including nuclear magnetic resonance and artificial intelligence, allows it to incapacitate the virus's infectious capabilities swiftly. Dr. Platt believes this breakthrough will appreciably alter how respiratory infections are managed. The developments coincide with a notable shift in health policy, which could further enhance the impact of ProLectin-M.
Dr. Leslie Ajayi, Bioxytran’s Chief Medical Officer, highlights the favorable conditions arising from a shift in vaccine resource allocations, stating that ProLectin-M could emerge as the first-line treatment option for healthy patients suffering from respiratory ailments.
Unique Therapeutic Approach of Bioxytran
Bioxytran's approach centers on Glycovirology, leveraging proprietary linear complex carbohydrates to hinder the galectins that hold viruses to host cells. In addition to the promising results against SARS-CoV-2, studies are ongoing to evaluate ProLectin-M's efficacy against other viral infections like the Epstein-Barr Virus (EBV). The innovative foundation of Bioxytran can potentially reshape our understanding of viral treatment paradigms.
Broader Goals and Areas of Impact
Bioxytran is not solely focused on ProLectin-M. The company is committed to addressing critical medical implications across three primary technology platforms: virology, combating cancer metastasis, and enhancing oxygen transport. Their drug BXT-25 is also under development, which aims to revolutionize stroke treatment. Utilizing an FDA-approved device for detecting tissue oxygenation, BXT-25 could drastically reduce the time to diagnosis, improving patient outcomes significantly.
About Bioxytran, Inc.
As a forward-thinking company at the cutting edge of therapeutic innovation, Bioxytran is reshaping treatment methodologies for viral infections and beyond. Its commitment to advancing unique therapeutic solutions continues to set the stage for improved health outcomes and addresses several challenging medical conditions.
For additional inquiries or information, please contact:
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Frequently Asked Questions
What is ProLectin-M?
ProLectin-M is Bioxytran's promising broad-spectrum antiviral drug currently in clinical development, targeting respiratory viruses such as SARS-CoV-2 and influenza.
How does ProLectin-M work?
It neutralizes viruses by targeting specific folds on their spike proteins, effectively blocking their infectiousness and potentially redefining treatment protocols.
What milestones has Bioxytran achieved?
Bioxytran has successfully completed dosing in its clinical trials, demonstrating significant efficacy rates and advancing the drug towards potential FDA approval.
What other therapies is Bioxytran developing?
Besides ProLectin-M, Bioxytran also focuses on treatments for cancer metastasis and offers innovations like BXT-25 for stroke diagnosis and management.
Why is Bioxytran's work important?
Bioxytran's research is vital for advancing antiviral therapies, especially essential in the context of evolving viral diseases and public health challenges.
